Humana IVIG denied: how to appeal

Quick answer

If Humana denied your IVIG and immunoglobulin, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: 65 days from the notice (Medicare Advantage); 65 days from the notice (Part D); 90 days from the notice (TRICARE); at least 180 days (employer self-funded plans). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why Humana denies IVIG and immunoglobulin

Humana is among the top three Medicare Advantage carriers and also operates Tricare and a smaller commercial book. Medicare Advantage prior auth is the highest-volume denial category.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

The law that controls this appeal

Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).

At a glance

Humana appeals: the rule, the deadline and the next level, by plan type

Which row applies depends on the plan you hold, not on Humana's brand. Your ID card, the Summary Plan Description and the denial letter say which.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Medicare Advantage (Part C) A private plan that replaces Original Medicare. The card says Medicare Advantage, HMO, PPO or PFFS.	42 CFR Part 422, Subpart M (§§ 422.560 to 422.634). Coverage decisions must follow Original Medicare rules (42 CFR 422.101).	65 calendar days from the date on the denial notice to request the plan's reconsideration (42 CFR 422.582, as amended effective 1 January 2025).	Expedited: 72 hours. Standard pre-service: 30 days (7 days for Part B drugs). Payment: 60 days (42 CFR 422.590).	If the plan does not fully reverse itself it must send the case to the Independent Review Entity on its own (42 CFR 422.592); then an ALJ hearing when the amount in controversy meets the annual threshold, the Medicare Appeals Council and federal court. State external review does not apply.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.
TRICARE Active-duty families, retirees and their families. Claims are handled by Humana Military (East) or TriWest (West) under the Defense Health Agency.	32 CFR 199.10 (appeal and hearing procedures) and the TRICARE Operations Manual, Chapter 12. ERISA, the ACA appeal rules and state external review do not apply.	Reconsideration: 90 days from the date of the notice of the initial determination. Formal review by the Defense Health Agency: 60 days from the reconsideration decision. Hearing: 60 days from the formal-review decision (32 CFR 199.10).	Expedited review is available for pre-admission and pre-authorization denials; the contractor's clock for a standard reconsideration is stated in the letter.	Formal review by the DHA, an independent hearing when the amount in controversy meets the threshold in 32 CFR 199.10(d), and a final decision by the DHA Director.
Employer self-funded plan (ERISA) Most large employers. The employer pays the claims and hires the carrier to administer them; the Summary Plan Description says self-funded or self-insured.	ERISA § 503 (29 U.S.C. § 1133) and the claims-procedure rule, 29 CFR 2560.503-1. Federal external review under 45 CFR 147.136(d) for non-grandfathered plans.	At least 180 days from the adverse benefit determination (29 CFR 2560.503-1(h)(3)(i)).	Urgent care: 72 hours. Pre-service: 30 days. Post-service: 60 days (29 CFR 2560.503-1(i)(2)).	Federal external review by an accredited independent review organization, requested within 4 months of the final internal denial (45 CFR 147.136(d)); then a civil action under ERISA § 502(a). State insurance departments do not regulate self-funded plans; the U.S. Department of Labor does.

Medicare Advantage (Part C)

What you can demand. The plan may not apply internal criteria that are more restrictive than Medicare's national and local coverage determinations, and must decide medical necessity on your individual circumstances (42 CFR 422.101(b), (c)). You can ask for the case file and the criteria used.

How to open the appeal. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

TRICARE

What you can demand. The sponsor, the beneficiary, a participating provider or an appointed representative can appeal. Ask the contractor for the file and the medical-necessity criteria it applied.

How to open the appeal. Cite 32 CFR 199.10 and the benefit rule in 32 CFR 199.4: state the appeal type, address it to the regional contractor named on the letter, and request the criteria used.

Employer self-funded plan (ERISA)

What you can demand. The plan must give you the claim file, the internal rule or criterion it relied on, and the identity of the reviewer, free of charge, on request (29 CFR 2560.503-1(h)(2)(iii), (m)(8)).

How to open the appeal. Cite ERISA § 503 and 29 CFR 2560.503-1 in the opening paragraph: request the claim file and the specific criteria relied on, and note the 30-day (pre-service), 60-day (post-service) and 72-hour (urgent) decision clocks.

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What Humana denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
Continuation after the initial authorization period when response is not documented
Dose or frequency above the policy's stated range
Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical Humana IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Diagnosis not on the plan's list of covered indications
Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
No documented failure of first-line therapy where the policy requires it
Response to prior IVIG cycles not documented in measurable terms
Plan classifies the use as experimental or investigational

The Humana appeal process

Appeal levels: Medicare Advantage federal 5-level ladder. Commercial: internal then external review.

Carrier timing: Medicare Advantage: 65 days from the notice for plan reconsideration, automatic forwarding to the IRE, then 60 days for each later level. Commercial: 180 days from denial for internal; generally at least 4 months (120 days) for federal external review (varies by plan and state).

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about Humana: Humana cases benefit most from level-2 (Maximus) escalation. We don't stop at level 1.

Common Humana denial patterns for IVIG and immunoglobulin

Five-level Medicare appeal process. Humana Medicare Advantage denials enter the federal appeal ladder: plan reconsideration → IRE (Maximus) → ALJ → Medicare Appeals Council → federal court. Federal data show Medicare Advantage plans overturn a large share of denials once they are appealed, yet very few members appeal; reversal odds stay meaningful through the IRE and ALJ levels.
DME (durable medical equipment) denials. Humana DME denials often cite missing home-evaluation documentation. Re-filing with the home-evaluation packet attached is the most common reversal path.
Skilled nursing and post-acute care. Humana has been the subject of CMS audits on early termination of skilled nursing coverage. Appeals citing CMS coverage manual standards have a documented success record.

How to win your Humana IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against Humana, that strategy rides on this procedural spine:

Procedural-rights anchor. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself. If your Humana coverage is a different plan type (Medicare Part D, TRICARE, Employer self-funded plan), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. Humana frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
Treating-provider attestation. A letter from the treating physician addressing each criterion in Humana's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your Humana IVIG and immunoglobulin appeal

The denial letter naming the criterion or policy applied
Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
Record of prior therapies and outcomes
Infusion records showing dose, frequency, and documented response
The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Humana IVIG and immunoglobulin appeals: frequently asked questions

Humana says IVIG is experimental for my condition. Can that be appealed?

Yes. 'Experimental or investigational' determinations are appealable internally and are expressly within the scope of external review. The strongest appeals identify the published guideline or evidence the specialist relies on and show it directly.

My infusions are scheduled this week. What do I do first?

Ask for an expedited appeal in writing and have the prescriber confirm that delay could seriously jeopardize health. Expedited decisions are due within 72 hours.

Humana approved IVIG before. Why is it denied now?

Continuation reviews look for measurable response. If the record only says 'doing well', the plan may treat that as no evidence. The specialist's note should record the objective measures the policy asks for.

Does Humana have to tell me which policy it used?

For employer and ACA plans, yes: the internal rule, guideline, or protocol relied on must be provided free on request. Ask for it by name in the appeal.

What Apellica does for Humana IVIG and immunoglobulin appeals

We file appeals against Humana specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Humana appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Humana IVIG and immunoglobulin appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Humana denied your IVIG and immunoglobulin? Here is what to do next